Evercore ISI Group analyst Jonathan Chappell upgrades Canadian National Railway (NYSE:CNI) from In-Line to Outperform.
AstraZeneca’s Drug Shows Promise In Copper Build-Up Genetic Disease
AstraZeneca plc (NASDAQ:AZN) reported high-level results from the FoCus Phase 3 trial evaluating ALXN1840 in Wilson disease. The study met the…